Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70258 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Julia Kopanz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Physical Examination, Hypoglycemic Agents, Clinical Trials, Phase III as Topic. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative 2 Joint Undertaking.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The aim of this study was to determine the purpose and use of physical examination (PE) in phase 3 and 4 drug interventional clinical trials within type 2 diabetes mellitus.
Methods
A total of 226 clinical trial protocols identified from the ClinicalTrials.gov database were systematically reviewed by five researchers. Data on trial and PE characteristics were extracted, including frequency and timing, purpose, elements and conduct of PE.
Results
A total of 211 protocols (59% phase 3, 72% two‐arm trials) were reviewed. Of these, 190 protocols mentioned a PE, and by distinguishing between different types of PE, a total of 241 PEs were assessed. Of the 190 protocols, 65% of protocols explicitly documented the purpose(s) for conducting a PE. PE was most often explicitly documented to identify adverse events (40%), followed by assessment of trial endpoints (33%), eligibility (21%), overall health status (3%) and characterization of the study population (1%). Sixty per cent of PEs described what was to be examined, and 8% specified how the PE should be conducted.
Conclusions
Protocols often lacked information on the purpose, elements and conduct of the PE, which may negatively impact the consistency of clinical trials. With the purpose of PE being often not explicitly stated, it can be questioned whether a PE is needed in every clinical trial or if it is performed as a matter of routine. Future research is needed to investigate whether PE is always necessary in a clinical trial and to explore opportunities for PE in clinical trial innovations including decentralization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
- MEMO Research, Division of Cardiovascular Research, University of Dundee, Dundee, UK.
- Vaccine Research. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)-Public Health, Valencia, Spain.
- trialsathome.com.
ORCID-Profile: Julia Kopanz, Amy Rogers, Isla S Mackenzie
Förderung
- Innovative Medicines Initiative 2 Joint Undertaking
Zitieren
APA
Kopanz, J., Rogers, A., Pérez-Breva, L., Hall, E., Devaiah, P., Mackenzie, I. S., Lagerwaard, B., Grobbee, D. E., Zuidgeest, M. G. P., & Trials@Home consortium (2026). Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70258
Vancouver
Kopanz J, Rogers A, Pérez-Breva L, Hall E, Devaiah P, Mackenzie IS, et al. Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70258
BibTeX
@article{Kopanz2026,
author = {Kopanz, Julia and Rogers, Amy and Pérez-Breva, Lina and Hall, Emily and Devaiah, Prashasthi and Mackenzie, Isla S and Lagerwaard, Bart and Grobbee, Diederick E and Zuidgeest, Mira G P and Trials@Home consortium, Trials@Home consortium},
title = {Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70258}
}
EUVIMED